OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
4
Results
Show all
Save search
Copy query
Show results for
Unknown
(4)
Publication Date
Release Date
2022
(2)
2021
(2)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Not available
S-EPMC8808333
|
biostudies-literature
Cite
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Not available
S-EPMC10207856
|
biostudies-literature
Cite
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Not available
S-EPMC8362593
|
biostudies-literature
Cite
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.
Not available
S-EPMC9126186
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets